STOCK TITAN

Silence Therapeutics to Present at the Barclays Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Silence Therapeutics will present at the Barclays Global Healthcare Conference on March 11 at 4:10 p.m. EST. The presentation will be led by President and CEO Mark Rothera, providing an overview of the company’s developments in siRNA therapeutics for significant unmet medical needs. A live webcast will be available on the company’s website, with an archived replay post-conference. Silence's innovative RNAi technology targets the silencing of disease-related genes.

Positive
  • None.
Negative
  • None.

Silence Therapeutics to Present at the Barclays Global Healthcare Conference

4 March 2021

LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that its President and Chief Executive Officer, Mark Rothera, will present a company overview at the Barclays Global Healthcare Conference on Thursday, March 11th at 4:10 p.m. EST / 21:10 GMT.

A live webcast of the presentation can be accessed via the Investors section of the Company's website at www.silence-therapeucs.com. An archived replay of the webcast will be available on the Company's website following the conference.

Enquiries:

Silence Therapeutics plc
Gem Hopkins, Head of IR and Corporate Communications
ir@silence-therapeutics.com

 
Tel:  +1 (646) 637-3208
  Investec Bank plc (Nominated Adviser and Broker)
Daniel Adams/Gary Clarence

 
  Tel:  +44 (0) 20 7597 5970
European PR
Consilium Strategic Communications
Mary-Jane Elliott/ Angela Gray / Chris Welsh
silencetherapeutics@consilium-comms.com

 
Tel: +44 (0) 20 3709 5700

About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary messenger RNAi GOLD™ (GalNAc Oligonucleotide Discovery) Platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit https://www.silence-therapeutics.com/.


FAQ

When is Silence Therapeutics presenting at the Barclays Global Healthcare Conference?

Silence Therapeutics will present at the Barclays Global Healthcare Conference on March 11 at 4:10 p.m. EST.

Who is presenting for Silence Therapeutics at the conference?

President and CEO Mark Rothera will present for Silence Therapeutics.

Where can I watch the Silence Therapeutics presentation online?

The presentation can be accessed via the Investors section of Silence Therapeutics' website.

What is Silence Therapeutics known for?

Silence Therapeutics is known for developing siRNA therapeutics targeting diseases with significant unmet medical needs.

What are the products being developed by Silence Therapeutics?

Silence Therapeutics is developing SLN360 for cardiovascular risk and SLN124 for iron loading anemias.

Silence Therapeutics Plc American Depository Share

NASDAQ:SLN

SLN Rankings

SLN Latest News

SLN Stock Data

326.18M
37.75M
16.94%
62.77%
0.76%
Biotechnology
Healthcare
Link
United States of America
London